Brand and Other Names:Ranexa
- Classes: Antianginal, Non-nitrates
Dosing & Uses
Dosage Forms & Strengths
500 mg PO BID initially; may increase to 1,000 mg PO BID, if needed
May be used concomitantly with beta blockers, nitrates, calcium channel blockers, antiplatelet therapy, lipid-lowering therapy, ACE inhibitors, and ARBs
Strong CYP3A4 inhibitors of inducers: Contraindicated
Coadministration with moderate CYP3A4 inhibitors: Not to exceed 500 mg PO BID
Coadministration with P-gp inhibitors (eg, cyclosporine): May require downward titration
Renal impairment: Cmax increases between 40-50% in patients with mild, moderate, or severe renal impairment
- Contraindicated for all degrees of hepatic impairment, due to 3-fold increased risk of QT prolongation
- Mild (Child-Pugh A): Cmax increases 30%
- Moderate (Child Pugh B): Cmax increases 80%
Swallow tablets whole; do not crush, chew, or split
<18 years: Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Prolonged QT interval
Neurologic: Tremor, paresthesia, hypoesthesia
Hypoglycemia (in diabetic patients on antidiabetic medication)
Hepatic cirrhosis, including Child-Pugh class A (mild), B (moderate), and C (severe)
Strong CYP3A inhibitors (eg, ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir)
CYP3A inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, St. John’s wort)
Not for acute anginal episodes
While ACS patients appear not to be at increased risk for proarrhythmia or sudden death, ranolazine has been shown to block I-Kr and cause dose-related QTc-interval prolongation
Little data available on high doses (ie, >1000 mg BID), long exposure, concomitant use with QT interval-prolonging drugs, or potassium channel variants causing prolonged QT interval
Increased risk of QTc prolongation in patients with mild or moderate hepatic impairment
Acute renal failure reported in some patients with severe renal impairment (CrCl <30 mL/min); discontinue if marked increase in creatinine occurs with increased BUN
Individuals >75 years have higher incidence of adverse effects
Causes small reductions in HbA1c in patients with diabetes; must not be considered a treatment for diabetes
Avoid grapefruit products
Pregnancy & Lactation
Pregnancy category: C
Lactation: Unknown if excreted in breast milk; discontinue or do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Antianginal effects not determined, but does not depend on HR or BP reduction; no effect on rate-pressure product at maximal exercise; shown to inhibit cardiac late sodium current (INA) at therapeutic levels
Bioavailability: 76%; absorption is highly variable but is unaffected by food
Peak plasma time: 2-5 hr
Protein bound: 62%
Intestine and liver (CYP3A4 and CYP2D6)
Enzymes inhibited: CYP3A4 (weak); CYP2D6 (moderate); both in vitro
Half-life: 7 hr
Excretion: Urine (75%), feces (25%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs